

Bardia Farzamfar, Pharm D, Ph D

Employment

Jan 2007- Present Gooya Innovative Biotech Tehran, Iran
(NoAvari Zisti Gooya)

Co-Founder, Senior Scientist and Chairman

- This company is the largest manufacturer of cell culture media in the Middle East. The company is main supplier of the most important Pharma/Biotech private companies and most public Research Institutes. Company has expertise in Media optimization for the best condition of different cell lines growth and expression, large scale production of standard and costume-made cell culture media.

Jan2004-2008 RosePharmed(ParsRoos) Tehran, Iran

Deputy Director for Production and Pharmaceutical Research and Development

- This company is established to make research, develop and production of novel drugs against life threatening diseases. The most important products of this company are IMOD™ for management of HIV/AIDS and ANGIPARS™ for treatment of Diabetic Foot Ulcer, NEUROTEC™ for Diabetic Neuropathy and SEPTIMEB™ for management of Septic Shock in ICU.

Jan 2003- Jan 2004 Ronak Biopharmaceutical Co Tehran, Iran

Managing Director

- This company is established to produce peptide and protein and other Biotechnology-based injectable preparations

Feb 2001- Sep 2007 Pasteur Institute of Iran Tehran, Iran

Executive Director of Biotechnology Process Development Center

- This center produce HIV1/2 screening kit as main product and developed gamma interferon, gp63 recombinant antigen (candidate vaccine for leishmaniasis).

Nov1997 – Jan 2003 Pasteur Institute of Iran Tehran, Iran

Head of Documentation Department

Aug.-Nov. 1997 Exir Pharmaceutical Company, Borojerd, Iran

Head of Antibiotic Production Department

Aug1995 - Aug1997 NAJA2 Hospital, Tehran, Iran

Responsible Pharmacist as Military service

May1994-Aug 1995 Shafa pharmacy, Borazjan, Iran

Responsible Pharmacist(Special program for male students before graduation)

Educatuion

1988-1994 Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Pharm. D.

Advisors: 1) A. Shafiee, Dean and Professor of Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS),

2) A. Ghanbarpoor, Ph.D., Professor of Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS),

Jan 2003- Dec 2006 Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Ph. D. in Medical Biochemistry

Advisors: 1) M. Zahraie, Ph.D., Professor of Faculty of Medicine, Tehran University of Medical Sciences (TUMS),

2) F. Mahboudi, Ph.D., Associate Professor, Pasteur Institute of Iran

International Patents

- 1- Use of a combination of ethanolic *rosa* sp., *urtica dioica* and *tanacetum vulgare* extracts, further comprising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for immunostimulation and/or treatment of HIV infections. INVENTORS: NOVITSKY YURY ALEXEVICH (RU); MADANI HESSAMEDIN (IR); GHARIBDOUST FARHAD (IR); FARHADI MOHAMMAD (IR); **FARZAMFAR BARDIA (IR)**; MOHRAZ MINOO (IR), PUBLICATION NUMBER: WO200708782, PUBLICATION DATE: 2007-08-09, APPLICATION NUMBER: WO2006EP00820 20060131 PRIORITY NUMBER: WO2006EP00820 20060131 (Referred as IMOD trade name in Iran)
- 2- Herbal extracts for treatment of diabetic foot ulcers, bed sores and other chronic wounds: INVENTORS: **FARZAMFAR BARDIA (IR)**; NOVITSKY YURY ALEXEVICH (RU); MADANI HESSAMEDIN (IR); GHARIBDOUST FARHAD (IR); FARHADI MOHAMMAD (IR); SADEGHI BEHNAM (IR),

KHORRAMKHORSHID HAMIDREZA (IR). FILING DATE: 2007-10-26, APPLICATION NUMBER: 07020966.3. European patent office, Munich (Referred as ANGIPARS trade name in Iran)

National Patents

1. New Serum Free Cell Culture Media Formulation for growth of Chinese Hamster Ovarian Cells (CHO) and protein expression in these cells, 2013, under process
2. New Aflatoxin measurement ELISA-Based Kit using HRP-BSA-AFB1 specific conjugate registered in Iranian company and Industrial properties registration office under No 38508438 dated Nov 2006.

International Publications

Official Farsi Translation of " Pulmonary Hypertension, Patient Survival Guide" under supervision and License of "Pulmonary Hypertension Association" Meryland, USA.2010

"Diabetic Foot Ulcer" Chapter in international Book entitled" Gangrene Management - New Advancements and Current Trends, ISBN 978-953-51-1061-3, edited by Alexander Vitin, 2013

National Academic and non-academic Awards

1- Book of the year of Iran, in Practical Sciences, 2000

For translation of "Essentials of Medicinal Chemistry" written by Anderjus Korolkovas, Dr. A. Shafiee & Dr. B. Farzamfar ,chosen among 960 Book title candidates

2- The Best Academic Book of Iran, Tehran University, 1998

For translation of "Essentials of Medicinal Chemistry" written by Anderjus Korolkovas, Dr. A. Shafiee & Dr. B. Farzamfar:

3- SELECTED WRITER during 60 years experience of Tehran University Publication, 2006

4-Honors of national Development of Iran's Industries.2011

5; Selected as one of the Best entrepreneur in the field of Biotechnology for Establishment and launching G. Innovative Biotech company, chosen by Iranian Presidential Deputy for Science and Technology 2012

Scientific articles

- 1- **Farzamfar B**, Minaie B, Mobtaker M, Salari P., Khorasani R, Baeeri M, Fallah S, Abdollahi M, Effect of Electromagnetic form of *Mellilotus Officinalis* extract on dermal wound healing in diabetic mice, *Pharmacologyonline*, 2008, 2: 246-254
- 2- **Farzamfar B**, Abdollahi M, Naabinejadian S, Heshmat R, Shahhosseiny MH, Novitsky YA, Farhadi M, Sub chronic toxicity of a novel herbal-based formulation (Semelil) on dogs, *DARU*,2008, Vol 16, Suppl 1
- 3- **Farzamfar B**, Bayanolhagh S., Mahboudi F, Zahraie M, The Effect of Different Stabilizers on Stability of Horseradish peroxidase- Bovine serum albumin-aflatoxin B1, a Conjugated Tracer for Detection of Aflatoxin B1 in Immunoassay- Based Methods, *Iranian Journal of pharmaceutical Research*, 2007, 6 (3) p. 179-84,
- 4- **Farzamfar B**, Khorramkhorshid HR , Sadeghi B, Madani H, Study of genotoxic potential of IMOD™ using SOS-Chromotest. *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S14,
- 5- **Farzamfar B**, Khorram Khorshid HR, Madani H, Sadeghi B, Study of dominant lethal effects of IMOD™ in mice. *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S13
- 6- **Farzamfar B**, Bayanolhagh S, Alinezhad M, Mahboudi F, Evaluation of Immunogenicity of dominant epitopes of hepatitis C

virus in Iranian subjects, *Iranian Journal of Biochemistry and molecular biology*, 2005, 1(1), p137

- 7- **Farzamfar B**, Ghanbarpoor A and Shafiee A. Synthesis, of some derivatives of trisubstituted pyrazoles and substituted (1-methyl-5-nitro-2-imidazolyl) pyrimidinones. *Journal of Science I.R. Iran*, 1995, 6, 223
- 8- Zahraie M, **Farzamfar B**, Bayanolhagh S, Rahimi AA, Matinizadeh M and Heshmat R, The Arg16Gly polymorphism of β 2-Adrenergic receptor gene and its association with hypertension in Iranian subjects, *International J of PharmTech Research*, 2010, Vol 2., No 4., Oct-Dec.
- 9- Khairandish P, Mohraz M, **Farzamfar B**, Abdollahi M, Shahhosseiny MH, Madani H, Sadeghi B, Heshmat R, et al, Preclinical and Phase 1 clinical safety of Setarud (IMOD™), a novel immunomodulator, *DARU*, 2009, 17(3):148-56
- 10- Khorshid HR, Azonov JA, Novitsky YA, **Farzamfar B**, Shahhosseiny MH, Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats, *Indian J Gastroenterol.*, 2008;27(3):110-2.
- 11- Khorramkhorshid HR, Novitsky YA, Abdollahi M, Shahhosseiny MH, Sadeghi B, Madani H, Rahimi R, **Farzamfar B**, Studies on potential Mutagenic and genotoxic activity of Setarud, *DARU*, 2008, 16(4): 223-8
- 12- Abdollahi M, **Farzamfar B**, Salari P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH, Evaluation of acute and sub-chronic toxicity of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing in rodents, *DARU*, 2008, Vol 16, Suppl 1
- 13- Khorram Khorshid HR, Sadeghi B, Abdollahi M, Salary P, Heshmat R, **Farzamfar B**, Madani SH, In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™) *DARU*, 2008, Vol 16, Suppl 1

- 14- Khorram Khorshid HR, **Farzamfar B**, Sadeghi B, Madani SH, Shah hoseiny MH, Study of mutagenic activity of IMOD™ using Ames method. *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S 13
- 15- Sadeghi B, **Farzamfar B**, Khorram Khorshid HR, Evaluation of Immunosensitizing potential of IMOD™ by popliteal lymph node assay, *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S12
- 16- Khorram Khorshid HR, **Farzamfar B**, Madani SH, Sadeghi B, Investigation of genotoxicity of IMOD™ in the bone marrow cells in mice, *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S12
- 17- Bayanolhagh S, **Farzamfar B**, Khorram Khorshid HR, Madani SH, Study of cytokine producing cells in blood samples of HIV-positive patients after in vivo IMOD™ Stimulation. *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S 10
- 18- Bayanolhagh S, **Farzamfar B**, Khorram Khorshid HR, Measurement of cytokine release by in vitro IMOD™ stimulation of human peripheral blood mononuclear cells using the ELISPOT assay. *Iranian Journal of Allergy, Asthma and Immunology*, 2007, 6 (Supp.6) S 8
- 19- Mahboudi F, Irina NA, Chevalier A, Ghadiri A, Adeli A, Amini-Bavil-Olyaei S, Barkhordari F, **Farzamfar B**, Alinejad MA , Serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli. *J Biotechnology*, 2006, 1; 125 (2): 295-303.
- 20- Zavar Reza J, Dousti M, Soleimani S, Asadi F, **Farzamfar B**, Aria Barzin S, Jalilian A, Effects of Persian walnut (Lavasanat region) oil extract on lipid profile in animal model (hypercholesterolemic

male rats), *Iranian Journal of Diabetes and Lipid Disorders*, 2006, 5(4) 319-24

- 21- Bayanolhagh S, Alinezhad M, Aseminia A, **Farzamfar B**, Mahboudi F, Design of a competitive sandwich ELISA method for detection of biological impurities in recombinant products which are produced in *Escherichia coli*, *Iranian Journal of Biochemistry and molecular biology*, 2005, 1(1), p137

Languages

1-English (Fluent)

2-French (Basic)

3-Spanish (Basic)

4- German (Basic)

**Congress and
Conference
Participation as
speaker**

1. Pulmonary Hypertension in Iran, Presented in Biannual Pulmonary Hypertension Association Conference, International Leaders Summit, Orange county, USA, June 2010
2. Study of genotoxic potential of IMOD™ using SOS-Chromotest. Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
3. Study of dominant lethal effects of IMOD™ in mice. Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
4. Study of mutagenic activity of IMOD™ using Ames method. Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
5. Evaluation of Immunosensitizing potential of IMOD™ by popliteal lymph node assay, Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007

6. Investigation of genotoxicity of IMOD™ in the bone marrow cells in mice, Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
7. Study of cytokine producing cells in blood samples of HIV-positive patients after in vivo IMOD™ Stimulation. Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
8. Measurement of cytokine release by in vitro IMOD™ stimulation of human peripheral blood mononuclear cells using the ELISPOT assay. Presented in the First Annual AIDS Research Congress of Iran, 11 November 2007
9. Evaluation of 2000 HCV positive and negative Iranian samples with Iranian HCV ELISA test and comparison with confirmatory Blotting test, Presented in the 3rd National Congress of Biotechnology, Mashhad I.R.IRAN, Sep 2003.
10. Evaluation of Immunogenicity of Dominant Epitopes of Hepatitis C Virus in Iranian Subjects. Presented in the 8th Iranian Congress of Biochemistry & Medical Biology, 11-15 Sep 2005.
11. Design of a competitive sandwich ELISA method for detection of biological impurities in recombinant products which are produced in Escherichia coli, Presented in the 8th Iranian Congress of Biochemistry & Medical Biology, 11-15 Sep 2005.
12. Synthesis of 4-(1-methyl-5-nitroimidazole-2-yl)-6-aryl-2(1H)pyrimidinones. Presented in 9th Iranian Chemistry and Chemical Engineering Congress, Assr Enghelab Research Complex, Tehran, Iran, 1994.
13. Synthesis of some derivatives of phenyl pyrazolonitroimidazoles, peresented in third Iranian Seminar

of Organic Chemistry, 16-18 August 1994, Teachers Training University Qf Arak, Iran.

14. Production of ANTI-HIV1/2 Rec® screening test kit, Presented in 7th Iranian Seminar of Pharmaceutical Science(ISPS), Mashhad;26-28 Aug 2000

**Trainer, invited
speaker for
Scientific
workshops and
seminars**

International seminar of " Intellectual property rights and their impacts on Chemical Pharmaceutical and Biotechnology industries" held by Boehmert & Boehmert, Germany, SIPS, Jordan and Best BioPharma, Iran., Faculty of pharmacy, Tehran University of Medical Sciences, Supported by Iran food and Drug Deputy, Ministry of Health, Nov 2006 Tehran

International seminar for " Drafting and registration process of Patents in the field of Pharmabiotech and IT" held by Boehmert & Boehmert, Germany and Best BioPharma, Iran, Science and Technology Park, Tehran University, Supported by Iran National Science Foundation, Oct 2008.

E-course and Workshop on "GMP and quality assurance in Biological product. Sep-Nov 2006

Theory and practical GMP and GLP workshop in pharmaceutical and Biological Products at National Research Center of Genetic Engineering and Biotechnology (NRCGEB), Tehran, Iran , (10 days), Nov-Dec 2003

GLP workshop in Biological Products at National Food and Drug Control Laboratories, (20 Hours), Jul 2002

GCP workshop for clinicians at Tehran University of Medical Science with collaboration of WHO-TDR, May 2002

GLP Workshop in Biological Products at center for Research of Skin Disease and Leprosy, Tehran University of Medical Science, under a WHO-TDR grant. Sep 2001

cGMP in Biological Products Workshop at Pasteur Institute of Iran under supervision of WHO special programme for Research and Training in Tropical Disease (TDR). (30 Hours), Oct 2000

GMP Course at Persian Gulf Biotechnology Center, Qeshm Island, Iran. (20 Hours), May 2000

GLP Course at Persian Gulf Hospital, Qeshm Island, Iran. (15 Hours) Jan 2000

Quality Assurance course of Ph.D. students of Biological Preparations at Pasteur Institute of Iran as one unit. (24 Hours), 1998-2001

Special Training:

1-Dec. 1997 – May 1998

-Genetic Engineering and Biotechnology Center (CIGB) and
-National Center for Bioproducts (BioCen)

Training Subject: Aspects of Quality systems and ISO 9000 series, Total Quality Management, Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), Validation and Metrology, Inspection and Audit, Documentation, Statistical Quality Control and Quality Engineering.

2- June 2006

Obtaining, Enforcing and Evaluating Intellectual Property rights in Europe., Munich, Germany,

**Collaboration
in research and
production
programs**

Pulmonary Hypertension awareness raising Volunteer in Iran on behalf of Pulmonary Hypertension Association, MD, USA.

Iran Scientific advisor and representative of Boehmert & Boehmert Patent attorney office, Munich, Germany.

Senior Scientist and Team leader in Cell Culture Media Design and Optimization, G. Innovative biotech, Iran

Team Leader Scientist in Pharmaceutical Research and development of novel treatments for Diabetic Foot Ulcer and Management of AIDS, RosePharmed (Pars Roos).

Research coworker of "Project of recombinant vaccine against *Leishmania.major*"

TDR ID 961011

Research coworker of " Evaluation of Leishmania vaccine by leishmanisation" TDR ID 980827